证券代码：002365 证券简称：永安药业 公告编号：2026-06 潜江永安药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2026年1月22日14:30:00 网络投票时间：2026年1月22日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2026年1 月22日上午9:15—9:25,9:30-11:30 和下午13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的时间为：2026年1月22日 9:15—15:00期间的任意时间。 2、现场会议召开地点：湖北省潜江经济开发区广泽大道2号潜江永安药业股 份有限公司（以下简称"公司"）二楼会议室 3、召开方式：本次股东会采取现场投票和网络投票相结合的方式。 4、股权登记日：2026年1月16日（星期五） 5、召集人：公司董事会； 6、主持人：公司董事长 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Group 1 - The core point of the article is that Yong'an Pharmaceutical (002365) has disclosed its shareholder count, which is projected to reach 49,527 households by December 31, 2025 [1]

Group 1 - The company approved the absorption merger of its wholly-owned subsidiary, Hubei Ling'an Technology Co., Ltd., which will be dissolved after the merger, with all assets, debts, and rights transferred to the company [1][28]. - The board meeting held on January 6, 2026, had all seven directors participating and unanimously approved the merger proposal [1][28]. - The merger aims to optimize management structure, improve operational efficiency, and reduce management costs [28][33]. Group 2 - The company approved a daily related transaction with Hubei Tian'an Daily Chemical Co., Ltd., with a total transaction amount not exceeding RMB 40 million for the year 2026 [3][16]. - The board meeting saw two related directors abstaining from voting, with five votes in favor and none against [3][16]. - The independent directors had previously reviewed and approved the related transaction proposal before it was presented to the board [4][24]. Group 3 - The company also approved a framework agreement with Hubei Yongbang Engineering Technology Co., Ltd. for equipment processing and manufacturing, with a total amount not exceeding RMB 20 million for 2026 [4][37]. - Similar to the previous transaction, two related directors abstained from voting, and the proposal was approved with five votes in favor [4][37]. - The independent directors confirmed that the transaction is necessary for the company's production needs and does not harm the interests of shareholders [56]. Group 4 - The company scheduled its first extraordinary shareholders' meeting for January 22, 2026, to discuss the approved proposals [14][60]. - The meeting will allow shareholders to vote both in person and via online platforms, ensuring compliance with relevant regulations [60][70]. - The company will provide a detailed voting process for shareholders participating through the internet [70].

格隆汇1月6日丨永安药业(002365.SZ)公布，第七届董事会第十二次临时会议，审议通过了《关于与湖 北永邦工程技术有限公司签订<2026年度设备加工及制造框架协议>暨关联交易的议案》，同意公司及 其子公司与湖北永邦工程技术有限公司（简称"湖北永邦"或"乙方"）签署《2026年度设备加工及制造框 架协议》，委托湖北永邦提供满足公司及其子公司技术质量指标等要求的加工及制造业务，具体包括设 备制造安装、机电设备及管道安装等其他相关工程的业务，交易总金额不超过2,000万元人民币，协议 自本次董事会批准之日起生效，协议有效期一年。 ...

Group 1 - The core viewpoint of the article is that Yong'an Pharmaceutical (002365.SZ) is planning to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. to optimize management structure and improve operational efficiency [1] - The merger aims to reduce management costs and integrate quality resources within the company [1] - Upon completion of the merger, Ling'an Technology will be dissolved, and all its assets, debts, business operations, personnel, and other rights and obligations will be legally inherited by the company [1]

Core Viewpoint - The company plans to absorb its wholly-owned subsidiary, Hubei Ling'an Technology Co., Ltd., which will be dissolved post-merger, with all assets, debts, and obligations transferred to the company [1] Financial Data Summary - As of December 31, 2024, Hubei Ling'an Technology reported total assets of 180 million yuan, total liabilities of 83.71 million yuan, and net assets of 96.22 million yuan [1] - For the period from January to September 2025, the subsidiary generated operating revenue of 70.47 million yuan, but reported a net loss of 11.15 million yuan [1]

格隆汇1月6日丨永安药业(002365.SZ)公布，第七届董事会第十二次临时会议，审议通过了《关于与湖 北永邦工程技术有限公司签订<2026年度设备加工及制造框架协议>暨关联交易的议案》，同意公司及 其子公司与湖北永邦工程技术有限公司（简称"湖北永邦"或"乙方"）签署《2026年度设备加工及制造框 架协议》，委托湖北永邦提供满足公司及其子公司技术质量指标等要求的加工及制造业务，具体包括设 备制造安装、机电设备及管道安装等其他相关工程的业务，交易总金额不超过2,000万元人民币，协议 自本次董事会批准之日起生效，协议有效期一年。 ...

证券代码：002365 证券简称：永安药业 公告编号：2026-02 潜江永安药业股份有限公司 关于吸收合并全资子公司湖北凌安科技有限公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、吸收合并概述 为优化管理架构，提高运营效率，降低管理成本，整合优质资源，潜江永安 药业股份有限公司（以下简称"公司"或"永安药业"）拟对全资子公司湖北凌 安科技有限公司（以下简称"凌安科技"）进行吸收合并，合并完成后，凌安科 技将予以注销，其全部资产、债权、债务、业务、人员及其他一切权利与义务等 由公司依法承继。 公司于 2026 年 1 月 6 日召开了第七届董事会第十二次临时会议，审议通过 了《关于吸收合并全资子公司湖北凌安科技有限公司的议案》。董事会审议该议 案时，以同意 7 票、反对 0 票、弃权 0 票通过了该议案。 根据《深圳证券交易所股票上市规则》及《公司章程》的相关规定，本次吸 收合并不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组情形。本次吸收合并事项尚需提交公司股东会审议。 二、被合并方基本情况 公司名称：湖北凌安科技 ...

潜江永安药业股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为进一步完善潜江永安药业股份有限公司（以下简称"公 司"）的激励约束机制，充分调动董事和高级管理人员的积极性和创 造性，保证公司持续、健康、稳定发展，根据《中华人民共和国公司 法》、《上市公司治理准则》等有关法律、法规及《公司章程》的规 定，结合公司实际情况，特制定本制度。 第二条 本制度适用于下列人员： 第二章 薪酬管理机构 （一）董事，包括独立董事、非独立董事（含职工代表董事）； （二）高级管理人员，包括总经理、副总经理、财务总监、董事 会秘书以及其他董事会认定的高级管理人员。 第三条 董事和高级管理人员薪酬的确定遵循以下原则： （一）按劳分配与责、权、利相匹配的原则； （二）薪酬与公司效益及工作目标挂钩的原则； （三）薪酬与公司长远利益相结合原则，确保主营业务增长， 控 制短期行为，促进公司的长期、稳健发展； （四）薪酬坚持"有奖有罚，奖罚对等，激励与约束并重"的原 则。 第四条 公司董事、高级管理人员薪酬方案由公司独立董事专门 会议制定，明确薪酬确定依据和具体构成。公司董事薪酬方案由股东 会决定，并予以披露。高级管理人员的 ...